How Long Do You Live With Stage 5 Kidney Failure?

Survival with stage 5 kidney failure varies enormously depending on whether you receive dialysis, get a kidney transplant, or choose conservative management without either. For older adults on dialysis, median survival is roughly five and a half years, while those managed without dialysis typically live closer to one and a half to two and a half years. A kidney transplant extends life further still. But those are population-level medians, and individual trajectories depend on age, other health conditions, frailty, nutritional status, and access to care in ways that make any single number misleading.

What the Numbers Look Like on Dialysis

Most people diagnosed with stage 5 kidney failure eventually start dialysis, and the survival statistics reflect that path. In a large UK study of patients aged 70 and older, those who received dialysis had a median survival of about 67 months, or roughly five and a half years, from the time their kidney function dropped below the stage 5 threshold.¹ A separate prospective study found a median of about 42 months (three and a half years) for the dialysis group when measured from the point kidney filtration first fell below 15.² These studies focused on older adults, which is important context: younger people on dialysis tend to do better, and those with fewer coexisting illnesses fare better still.

For people with diabetes, the picture is harsher. Patients whose kidney failure stems from type 1 diabetes represent one of the most medically complex groups on dialysis, and their half-life from the start of treatment sits between roughly three and a half to five years.³ “Half-life” here means the point at which half the group has died, so it is essentially another way of expressing median survival. Diabetes accelerates cardiovascular disease and infection risk, both of which are leading killers at this stage.

How a Kidney Transplant Changes the Picture

A functioning kidney transplant offers the longest survival of any treatment. Compared with staying on the transplant waiting list and continuing dialysis, receiving a deceased-donor kidney added roughly two and a half extra years of life over a ten-year follow-up period.⁴ That advantage grew with time: at five years the benefit was more modest, but by ten years it was substantial.

The survival advantage of transplantation is not limited to young, healthy candidates. Research suggests that older patients and those with more health problems actually gain the greatest relative benefit from a transplant, even though their absolute survival is shorter than that of younger recipients.⁵ That finding runs against the intuition that transplant should be reserved for healthier patients. In practice, however, most people with stage 5 kidney failure never receive a transplant. Organ shortages, age cutoffs at some centers, and the presence of conditions that make surgery risky all limit access. For the majority, dialysis remains the primary treatment.

Survival Without Dialysis

Some people, particularly older adults with significant frailty or multiple serious illnesses, choose not to start dialysis at all. This approach, sometimes called conservative kidney management, focuses on slowing decline and managing symptoms rather than replacing kidney function mechanically. Median survival in one study of patients managed this way was about 16 months after their filtration rate dropped below 10, and roughly a third of them survived beyond one year from that point.⁶ In the UK comparison study, conservative management patients had a median survival of about 21 months from entering stage 5, compared with 67 months for those on dialysis.¹

The gap narrows when you look at patients whose kidney function is very low. Once the filtration rate drops below 10, the dialysis group’s median survival was about 36 months compared with 12 months for those managed conservatively.² That is still a meaningful difference, but it is smaller than the raw numbers first suggest because the people choosing conservative care tend to be older and sicker to begin with. Age, blood protein levels, and how far kidney function has fallen all independently predict shorter survival in this group.

An important finding is that conservative management does not automatically mean a rapid decline in how someone feels. In the study of patients managed without dialysis, more than half had symptoms that stayed stable or even improved over a 12-month period, and a similar proportion reported stable or improved quality of life.⁶ That is worth knowing, because the assumption that forgoing dialysis means immediate suffering is not always correct.

What Actually Kills People at This Stage

Heart disease and infection are the two dominant causes of death once kidney function is severely reduced. In clinical trials of patients with advanced kidney disease, cardiovascular events accounted for roughly 30 to 40 percent of all deaths, and infections accounted for another 25 to 30 percent.⁷ Among cardiovascular deaths, sudden cardiac death was the single most common type, particularly in dialysis patients.⁸

The relationship between kidney function and heart disease is not subtle. In a large study tracking causes of death by kidney function level, the proportion dying from cardiovascular disease rose steadily as filtration rate declined, from about 21 percent in people with mild kidney impairment and protein in their urine, up to nearly 44 percent in those with more severely reduced function. Heart failure and valve disease specifically became more common as kidneys worsened, while the proportion dying from cancer fell.⁹ This is one reason why managing blood pressure, fluid balance, and heart health is so central to extending life at stage 5.

Infection deserves its own mention. Dialysis access points, whether fistulas, grafts, or catheters, create entry points for bacteria. The immune system is also weakened by kidney failure itself. Infection accounted for more than half of all non-cardiovascular deaths in one advanced kidney disease trial.⁸ Preventing infections through good catheter care, timely vaccinations, and early treatment of any signs of infection can make a real difference in how long someone survives.

Peritoneal Dialysis Versus Hemodialysis

The two main forms of dialysis are hemodialysis, which filters blood through an external machine usually three times a week at a clinic, and peritoneal dialysis, which uses the lining of the abdomen as a filter and can be done at home. Whether one is better for survival is a question that has generated conflicting research, and the answer depends heavily on the time frame you are looking at.

In the first two years, peritoneal dialysis appears to hold an edge. One study using statistical methods designed to account for the fact that patients who start peritoneal dialysis tend to be younger and healthier found that peritoneal dialysis was associated with roughly half the mortality risk of hemodialysis during the first two years.¹⁰ But that advantage fades. A meta-analysis focused on older adults found that mortality rates between the two types were similar through the first two years, after which peritoneal dialysis began to show higher mortality at three, four, and five-to-ten years.¹¹ A large retrospective study confirmed this pattern: no difference through four years, but significantly higher five- and ten-year mortality in the peritoneal dialysis group.¹²

One factor that helps explain this crossover is residual kidney function, the small amount of filtering your own kidneys still do even after reaching stage 5. Peritoneal dialysis tends to preserve that residual function longer than hemodialysis, and residual function is independently linked to better survival.¹³ Once that residual function disappears, as it eventually does for most people, the advantage of peritoneal dialysis may erode. This does not mean peritoneal dialysis is a bad choice. Many people value the independence and flexibility of a home-based treatment, and starting with peritoneal dialysis and switching to hemodialysis later is a perfectly reasonable strategy.

Factors That Shift Survival the Most

Population-level survival figures obscure enormous individual variation. Several factors consistently predict whether someone will land on the longer or shorter end of the range.

Age is the most powerful single predictor, which is no surprise. But the specific interaction between age and treatment choice matters. In younger patients, dialysis confers a large survival advantage over conservative management. In very elderly patients with multiple serious conditions, the gap narrows considerably, and the quality-of-life burden of dialysis becomes a more significant factor in the decision.

Frailty, which captures overall physical vulnerability beyond what a list of diagnoses tells you, is an independent risk factor for death at every stage of kidney disease.¹⁴ Even after accounting for age, sex, and the number of other diseases present, being frail roughly triples the risk of dying for people with end-stage kidney disease.¹⁵ This means that two 75-year-olds on dialysis can have very different prognoses depending on whether they are physically robust or frail, even if their lab work looks similar.

Nutritional status is closely intertwined with frailty. The combination of poor appetite, dietary restrictions, protein loss during dialysis, and the inflammation that accompanies kidney failure often leads to a wasting syndrome where muscle mass and body stores of protein and energy steadily erode. This wasting is common in stage 5 kidney disease and is linked to a higher risk of dying from cardiovascular disease.¹⁶ Muscle loss specifically feeds back into frailty, creating a cycle that is difficult to break.¹⁷ Monitoring weight, blood protein levels, and muscle function, and intervening early with dietary support, can be genuinely life-extending.

Socioeconomic factors also play a measurable role. Lower income is associated with faster progression to kidney failure and higher mortality once on dialysis. In one large U.S. cohort, low income was linked to a roughly 50 percent higher risk of reaching end-stage kidney disease in the first place.¹⁸ Among young adults on dialysis, racial disparities in survival were significantly larger in low-income neighborhoods than in wealthier ones, suggesting that economic context amplifies or dampens other risk factors.¹⁹ Access to nephrology care before reaching stage 5, timely placement of a good dialysis access site, and access to transplant evaluation all correlate with income and insurance in ways that affect survival.

Survival Rates Have Been Improving

If you are looking at older survival statistics, the picture today is somewhat brighter. In the United States, the excess risk of dying from kidney failure dropped by 12 to 27 percent over each five-year interval between 1995 and 2013, with the biggest relative improvements in younger patients and those with a functioning transplant.²⁰ European data show a similar trend: excess mortality from kidney failure declined substantially over time for adults on dialysis.²¹ These gains come from better dialysis technology, improved cardiovascular management, wider use of transplantation, and earlier nephrology referral. They do not change the fundamental biology of kidney failure, but they mean that survival figures from studies conducted in the 1990s or early 2000s probably underestimate how long people live today.

One sobering exception in the European data: older transplant recipients (65 and over) did not show clear improvement and may have experienced worsening excess mortality over time.²¹ This may reflect the expanding use of transplants in older and sicker patients who would not have been considered candidates a generation ago.

When Dialysis Starts and Whether Earlier Is Better

You might assume that starting dialysis sooner, before kidney function drops to extremely low levels, would buy more time. The evidence does not clearly support that assumption. A large study found that starting dialysis at a higher level of residual kidney function was actually associated with increased mortality compared with starting later.²² A systematic review of the question found mixed results: some studies showed no connection between timing and outcomes, some showed worse outcomes with early starts, and a minority showed benefit from earlier initiation.²³

The likely explanation is that patients who start dialysis earlier often do so because they are sicker, with more fluid overload or more severe symptoms, rather than because they planned a proactive early start. This makes early-start groups look worse in studies even if the timing itself was not the problem. The current clinical consensus leans toward starting dialysis when symptoms demand it or when complications like dangerous fluid retention or electrolyte imbalances develop, rather than hitting a particular kidney function number on a lab test.

Predicting Your Personal Prognosis

Given the wide variation in survival, researchers have developed scoring tools that combine several measurable factors to estimate an individual’s risk. One such tool built for patients starting hemodialysis uses six items: how much residual kidney function remains at the start, blood protein levels, calcium levels, the burden of other diseases, functional status, and whether certain medications are being used. Each factor contributes points, and the total score predicts the probability of dying in the first year.²⁴ These scores are not destiny. They are statistical summaries meant to help doctors and patients have more honest conversations about what to expect and whether aggressive treatment is likely to help.

In practice, your nephrologist’s clinical judgment, informed by your functional status, nutritional health, heart function, and response to early treatment, often gives a better sense of your trajectory than any single number. Ask directly. Most kidney specialists are willing to have frank conversations about expected survival once you signal that you want to hear the answer.

Symptom Burden and Quality of Life

Survival in months matters, but so does what those months feel like. People with stage 5 kidney failure managed without dialysis carry a symptom burden that matches or exceeds what is seen in terminal cancer and other end-of-life populations.²⁵ Fatigue, breathlessness, drowsiness, pain, and itching are among the most common complaints. Dialysis relieves some symptoms, particularly fluid-related breathlessness, but introduces others, including fatigue on dialysis days, dietary restrictions, and the time burden of treatment itself.

A cross-sectional study comparing quality of life between people on dialysis and those managed conservatively found that the dominant predictors of poor self-reported health differed between the groups. For conservatively managed patients, difficulty performing daily activities, drowsiness, and shortness of breath were the strongest drivers of low quality of life. For those on dialysis, reduced ability to care for themselves and lack of energy stood out.²⁶ Neither group had an obviously easy time. The decision between dialysis and conservative management is often less about maximizing months and more about which set of trade-offs a person can live with.

Palliative care, whether integrated into ongoing dialysis treatment or provided as the primary approach for someone choosing conservative management, can meaningfully reduce symptoms and improve quality of life.²⁷ Programs that combine nephrology and palliative care expertise in an interdisciplinary team have been well received by both patients and caregivers and have been linked to lower use of emergency and hospital services.²⁸ Palliative care is not the same as giving up. It can run alongside dialysis for years and is increasingly recognized as standard good practice for anyone with advanced kidney disease.

What Happens When Dialysis Stops

Some people who have been on dialysis for months or years eventually decide to stop, whether because of declining function, unbearable symptom burden, or a feeling that continued treatment is no longer worth it. Dialysis withdrawal is not rare: it accounts for a meaningful share of deaths among dialysis patients in many countries. In a study of 18 patients who discontinued hemodialysis after an average of nearly four years on treatment, the average time from the last dialysis session to death was about 10 days.²⁹ That is a small study, and individual variation exists, but the window is generally measured in days to a couple of weeks, not months. Toxins and fluid accumulate rapidly once dialysis stops, and organ systems that were barely being maintained tend to fail quickly.

For people considering this path, the relevant preparation is less about the medical details and more about ensuring comfort in those final days. Hospice care, advance directives, and clear communication with family about what to expect are the practical priorities. Medical teams experienced in kidney palliative care can manage fluid overload, nausea, and agitation in ways that keep the final days as comfortable as possible.

1
PubMed Central. Survival of elderly patients with stage 5 CKD: comparison of conservative management and renal replacement therapy
2
PubMed Central. Outcomes in dialysis versus conservative care for older patients: A prospective cohort analysis of stage 5 Chronic Kidney Disease
3
Diabetes mellitus. Early and long-term results of transplantation treatment of patients with stage 4–5 chronic kidney disease in the outcome of type 1 diabetes mellitus
4
JAMA Network Open. Survival Benefit of First Single-Organ Deceased Donor Kidney Transplantation Compared With Long-term Dialysis Across Ages in Transplant-Eligible Patients With Kidney Failure
5
PubMed Central. Life expectancy after kidney transplantation in a population-based retrospective cohort
6
PubMed Central. CKD in elderly patients managed without dialysis: survival, symptoms, and quality of life
7
European Heart Journal. Causes of death in patients with chronic kidney disease: insights from the ASCEND-D and ASCEND-ND cardiovascular outcomes trials
8
PubMed Central. Cause-Specific Mortality in Patients With Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial
9
PubMed Central. Cause of Death in Patients with Reduced Kidney Function
10
PubMed Central. Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis
11
PubMed Central. Mortality of Peritoneal Dialysis versus Hemodialysis in Older Adults: An Updated Systematic Review and Meta-Analysis
12
PubMed Central. Long-term mortality in patients with end-stage renal disease undergoing hemodialysis and peritoneal dialysis: a propensity score matching retrospective study
13
Kidney and Dialysis. Residual Kidney Function and the Impact of Dialysis Modality
14
PubMed Central. Frailty and chronic kidney disease: current evidence and continuing uncertainties
15
Nefrología (English Edition). Frailty in end stage renal disease: Current perspectives
16
PubMed Central. Protein-energy wasting and mortality in chronic kidney disease
17
PubMed Central. Crosstalk in the kidney-muscle axis: myokines and muscle-relevant mediators in chronic kidney disease-associated sarcopenia
18
PubMed Central. Socioeconomic Disparities in Chronic Kidney Disease
19
PubMed Central. Neighborhood socioeconomic status, race, and mortality in young adult dialysis patients
20
American Society of Nephrology. Survival Rates Are Improving for Individuals with Kidney Failure
21
PubMed. Survival improvements for Europeans with ESKD
22
PubMed Central. Timing of dialysis initiation and survival in ESRD
23
PubMed Central. Update of dialysis initiation timing in end stage kidney disease patients: is it a resolved question? A systematic literature review
24
PubMed Central. Risk Score to Predict 1-Year Mortality after Haemodialysis Initiation in Patients with Stage 5 Chronic Kidney Disease under Predialysis Nephrology Care
25
PubMed. Symptom management in patients with established renal failure managed without dialysis
26
PubMed Central. Factors associated with quality of life in patients with kidney failure managed conservatively and with dialysis: a cross-sectional study
27
PubMed Central. Palliative Care Interventions for Patients with Kidney Disease: A Scoping Review by the Kidney Disease Aging Research Collaborative
28
PubMed Central. Lived experiences and decision making among patients and caregivers choosing conservative kidney management: A qualitative study
29
PubMed. Dialysis discontinuation. A ‘good’ death?